Price$5.22-2.44 (-31.81%)
2026-03-042026-06-05
News · 26 weeks65+8%
2025-12-142026-06-07
Mix4790d
- SEC Filings15(32%)
- Insider12(26%)
- Other10(21%)
- Leadership5(11%)
- Dividends3(6%)
- Offering2(4%)
Latest news
25 items- SECPLUS THERAPEUTICS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- SECAmendment: SEC Form S-3/A filed by PLUS THERAPEUTICS Inc.S-3/A - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- PRPlus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical LaboratoryHOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program. The CAP Laboratory Accreditation Program is internationally recognized as the "gold standard" in laboratory accreditation. As part of this distinction, CNSide Diagnostics' laboratory un
- SECSEC Form S-3 filed by PLUS THERAPEUTICS Inc.S-3 - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- PRPlus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal MetastasesPlus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs by 40% Presentation receives blue-ribbon recognition at the ISPOR Annual Meeting, the premier global gathering for health economics and outcomes research HOUSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide ce
- PRPlus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS OncologyPartnership to deliver a novel AI-native integrated CNS oncology platform Platform will unify and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision neuro-oncology HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, today announces that it has signed an agreement to enter into a strategic partnership with Ephemeral Technologies ("Ephemeral") to deliver a unique AI execution platform for CNS oncology. The AI execution platform is designed to integrate, organize, and derive ac
- INSIDERSEC Form 4 filed by Director Van Es-Johansson An4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERSEC Form 4 filed by Director Hawkins Richard J4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERSEC Form 4 filed by Director Guse Kyle4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERSEC Form 4 filed by Director Clowes Howard4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERSEC Form 4 filed by Director Andrews Ronald Asbury4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Sims Andrew John Hugh Macintyre4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Hedrick Marc H4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- SECPLUS THERAPEUTICS Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- SECPLUS THERAPEUTICS Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- PRPlus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial RolloutHOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces financial results for the first quarter ended March 31, 2026 and provides an overview of recent and upcoming business highlights. "Our team remains focused on our two highest-priority 2026 goals, CNSide commercial scale-up and REYOBIQ pivotal-trial readiness," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "We continue to add payers for CNSide, including a fourth national payer, expanding cov
- SECSEC Form SCHEDULE 13G filed by PLUS THERAPEUTICS Inc.SCHEDULE 13G - PLUS THERAPEUTICS, INC. (0001095981) (Subject)
- PRPlus Therapeutics Receives Medicare Enrollment Approval for CNSide DiagnosticHOUSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced that its wholly owned subsidiary, CNSide Diagnostics, LLC ("CNSide Diagnostics"), has successfully enrolled in the Medicare program and received a Provider Transaction Access Number (PTAN) from the Centers for Medicare & Medicaid Services (CMS). This key milestone establishes CNSide Diagnostics as a Medicare-enrolled clinical laboratory, enabling the submission of claims for its CNSide® Cerebrospinal Fluid (CSF) Assay Platform, i
- PRPlus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerHOUSTON, April 28, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today a new payer coverage agreement with Blue Shield of California, effective April 2026, providing reimbursement for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay for patients with metastatic central nervous system cancers. Blue Shield of California joins a growing list of national and regional payers, including United Healthcare, Humana, and Highmark, that provide coverage for CNSide. The addition of Blue Shield of California expands CNSide's total covered lives from approximately 75 mill
- PRPlus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™HOUSTON, April 23, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced today the initiation of manufacturing activities and technology transfer with SpectronRx under a previously executed Master Services Agreement (MSA), in support of late-stage clinical manufacturing of Rhenium-186 and REYOBIQ. With SpectronRx serving as a second GMP manufacturing site alongside Radiomedix, and Rhenium-186 isotope supplied through Telix Pharmaceuticals, Plus strengthens the reliability of its multi-partner supply chain
- INSIDERSEC Form 4 filed by Daniels Eric Joseph4 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- PRPlus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)HOUSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that it has granted inducement awards to Eric J Daniels, M.D., its new Chief Development Officer who joined the Company on April 20, 2026. The awards were granted on April 20, 2026 under the Company's 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new employees as an inducement to join the Company. The inducement awards consist of options to purchase 20,000 shares of the Company common
- INSIDERSEC Form 3 filed by new insider Daniels Eric Joseph3 - PLUS THERAPEUTICS, INC. (0001095981) (Issuer)
- SECPLUS THERAPEUTICS Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)
- PRPlus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementHOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq determined that, for the 10 consecutive business days from April 6, 2026 to April 17, 2026, the closing bid price of the Company's common stock was at or above $1.00 per share. Accordingly, Nasdaq has advised that the matter
PSTV FAQ
6 questionsWhat does PLUS THERAPEUTICS Inc. do?
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx...Where does PSTV stock trade?
PLUS THERAPEUTICS Inc. (PSTV) is listed on NASDAQ.What sector and industry is PSTV in?
PLUS THERAPEUTICS Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about PSTV?
PLUS THERAPEUTICS Inc. has had 3 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $200.00 price target on 2026-02-03. Recent price targets range from $200.00 to $900.00.What companies are similar to PSTV?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare PSTV side-by-side with any of them on Quantisnow.How can I track PSTV on Quantisnow?
Quantisnow aggregates PLUS THERAPEUTICS Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PSTV to receive live email and push alerts on every new disclosure.